Can a common diabetes drug help transplant patients?
NCT ID NCT00466518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how sitagliptin (Januvia) affects levels of anti-rejection drugs and blood sugar in 16 people who had a kidney transplant and have type 2 diabetes. Participants took sitagliptin daily for 3 months. The goal was to see if it is safe and works well in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sitagliptin (Januvia)
What this could lead to
If successful, this could show that sitagliptin is a safe and effective option to help control blood sugar in kidney transplant patients with type 2 diabetes.
What could go wrong
This is a very small, early-phase study with only 16 participants, so results may not apply to everyone. The main goal was to check drug interactions, not to prove long-term benefits or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198-1230, United States